Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of ENX-102 and Determine a Dose-response for ENX-102 in Patients With Generalized Anxiety Disorder (GAD)
Conditions
Interventions
ENX-102
Placebo
Locations
3
United Kingdom
MAC Clinical Research
Liverpool, UK, United Kingdom
MAC Clinical Research
Blackpool, United Kingdom
MAC Clinical Research
Manchester, United Kingdom
Start Date
December 9, 2024
Primary Completion Date
June 23, 2025
Completion Date
June 23, 2025
Last Updated
September 17, 2025
NCT07477990
NCT00411398
Lead Sponsor
Engrail Therapeutics INC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions